/IDEXX%20sign%20at%20their%20offices%20in%20Silicon%20Valley_%20By%20Sundry%20Photography.jpeg)
IDEXX Laboratories has struggled to keep pace with the broader market over the past year, but Wall Street still sees plenty of room for the stock to recover, with analysts maintaining a moderately bullish...
Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. ...
IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today released its 2025 Corporate Responsibility Report , highlighting progress against the...
As data centers strain water systems, FIW, PHO, and CGW offer investors ETF-based access to water utilities, infrastructure, and equipment firms, each with distinct fees and concentration.
IDEXX Laboratories will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tuesday, August 4, 2026, before...
/Idexx%20Laboratories%2C%20Inc_%20outside%20lab-by%20Sundry%20Photography%20via%20iStock.jpg)
IDEXX Laboratories has trailed the Nasdaq Composite over the past year, and analysts are fairly bullish on its future growth potential.
IDEXX Laboratories (NASDAQ:IDXX) President and CEO Michael Erickson used a Stifel investor conference appearance to emphasize the company’s innovation pipeline, expanding commercial reach and growing...
/Idexx%20Laboratories%2C%20Inc_%20phone%20and%20chart%20-by%20IgorGolovniov%20via%20Shutterstock.jpg)
Although IDEXX Laboratories has lagged the broader market over the past year, Wall Street analysts remain fairly bullish about the company’s long-term growth prospects.